表紙
市場調查報告書

CAR-T細胞療法的全球市場 - 產業分析,市場規模,佔有率,成長,趨勢,預測 2019年∼2026年

Global CAR T Cell Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2019 to 2026

出版商 Value Market Research 商品編碼 917581
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
CAR-T細胞療法的全球市場 - 產業分析,市場規模,佔有率,成長,趨勢,預測 2019年∼2026年 Global CAR T Cell Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2019 to 2026
出版日期: 2019年12月01日內容資訊: 英文 100 Pages
簡介

本報告提供全球CAR-T細胞療法市場調查,市場概要,各標的抗原、用途、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 報告概要
  • 調查範圍
  • 調查方法

第2章 摘要整理

第3章 產業分析

  • 簡介
  • 市場成長要素
  • 市場機會
  • 市場趨勢
  • 波特的五力分析
  • 市場魅力分析

第4章 價值鏈分析

  • 價值鏈分析
  • 原料分析
  • 潛在的買主的清單
  • 行銷流通管道

第5章 全球CAR-T細胞療法市場:各標的抗原

  • 市場概要
  • 市場分析:各標的抗原
  • CD 19
  • CD 20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • Meso
  • EGFRvlll
  • 其他

第6章 全球CAR-T細胞療法市場:各用途

  • 市場概要
  • 市場分析:各用途
  • 急性淋巴性白血病
  • 慢性淋巴性白血病
  • 非何杰金氏病白血病
  • 多發性骨髓瘤
  • 胰臟癌症
  • 神經芽細胞
  • 乳癌

第7章 全球CAR-T細胞療法市場:各地區

  • 市場概況
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 競爭情形

  • 競爭情形
  • 夥伴關係、合作、契約
  • 合併、收購
  • 新產品的銷售
  • 其他趨勢

第9章 企業簡介

  • 企業佔有率分析
  • 市場集中度
  • BELLICUM PHARMACEUTICALS, INC.
  • CELGENE CORPORATION
  • CELLECTIS
  • JUNO THERAPEUTICS
  • KITE PHARMA INC.
  • NOVARTIS INTERNATIONAL AG

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Value Market Research's latest report on the Global CAR T Cell Therapy Market identified a significant growth in the industry over the last few years and anticipates it to grow considerably within the forecast period of 2020-2026.

The global car t cell therapy market report provides a complete evaluation of the market for the forecast period. The report consists of various segments as well as an analysis of the factors playing a significant role in the market. The factors include the drivers, restraints, challenges and opportunities and the impact of these factors on the market has been provided in the report. The drivers and restraints are classified as intrinsic factors while the opportunities and challenges are classified as extrinsic factors of the market. The global car t cell therapy market study provides an insight on the developments of the market in terms of revenue throughout the specified period.

This report provides a complete analysis for the global car t cell therapy market. An in-depth secondary research, primary interviews and in-house expert reviews are responsible for providing the market estimates for the global car t cell therapy market. These market estimates have been put together by studying the impact of different social, political and economic factors along with the current market dynamics that are affecting the global car t cell therapy market growth.

The report begins with the market overview, followed by a crisp executive summary. The Porter's Five Forces analysis covered in this study will assist in understanding the five forces namely buyers bargaining power, suppliers bargaining power, threat of new entrants, the threat of substitutes and the degree of competition in the global car t cell therapy market. It also helps to explain the various participants such as system integrators, intermediaries and end users within the market. The report by Value Market Research also focuses on the competitive landscape of the global car t cell therapy market.

The market analysis involves a section exclusively to list the major players of the global car t cell therapy market wherein our analysts provide an insight into the financial statements of all the key players along with its key development product. The company profile section in the report also provides a business overview and financial information. The companies provided in this section can be customized as per the client's requirement.

The CAR T Cell Therapy Market Report Segments the market as below:

By Targeted Antigens

  • CD 19
  • CD 20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • Meso
  • EGFRvlll
  • Others

By Application

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Leukemia
  • Multiple Myeloma
  • Pancreatic Cancer
  • Neuroblasta
  • Breast Cancer
  • Acute Myeloid Leukemia
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others

TABLE OF CONTENTS

1. PREFACE

  • 1.1. REPORT DESCRIPTION
    • 1.1.1. OBJECTIVE
    • 1.1.2. TARGET AUDIENCE
    • 1.1.3. UNIQUE SELLING PROPOSITION (USP) & OFFERINGS
  • 1.2. RESEARCH SCOPE
  • 1.3. RESEARCH METHODOLOGY
    • 1.3.1. MARKET RESEARCH PROCESS
    • 1.3.2. MARKET RESEARCH METHODOLOGY
      • 1.3.2.1. SECONDARY RESEARCH
      • 1.3.2.2. PRIMARY RESEARCH
      • 1.3.2.3. MODELS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET HIGHLIGHTS
  • 2.2. GLOBAL CAR T CELL THERAPY MARKET: SNAPSHOT

3. CAR T CELL THERAPY - INDUSTRY ANALYSIS

  • 3.1. INTRODUCTION
  • 3.2. MARKET DRIVERS
    • 3.2.1. DRIVER 1
    • 3.2.2. DRIVER 2
  • 3.3. MARKET RESTRAINTS
    • 3.3.1. RESTRAINT 1
    • 3.3.2. RESTRAINT 2…
  • 3.4. OPPORTUNITIES
    • 3.4.1. OPPORTUNITY 1
    • 3.4.2. OPPORTUNITY 2
    • 3.4.3. OPPORTUNITY 3….
  • 3.5. TRENDS
    • 3.5.1. TREND 1
    • 3.5.2. TREND 2…
  • 3.6. PORTER'S FIVE FORCE ANALYSIS
  • 3.7. CAR T CELL THERAPY: MARKET ATTRACTIVENESS ANALYSIS
    • 3.7.1. MARKET ATTRACTIVE ANALYSIS BY TARGETED ANTIGENS
    • 3.7.2. MARKET ATTRACTIVE ANALYSIS BY APPLICATION
    • 3.7.3. MARKET ATTRACTIVE ANALYSIS BY REGION

4. VALUE CHAIN ANALYSIS

  • 4.1. CAR T CELL THERAPY: VALUE CHAIN ANALYSIS
  • 4.2. CAR T CELL THERAPY RAW MATERIAL ANALYSIS
    • 4.2.1. LIST OF RAW MATERIALS
    • 4.2.2. CAR T CELL THERAPY RAW MATERIAL MANUFACTURES LIST
    • 4.2.3. PRICE TREND OF CAR T CELL THERAPY KEY RAW MATERIALS
  • 4.3. LIST OF POTENTIAL BUYERS
  • 4.4. MARKETING CHANNEL
    • 4.4.1. DIRECT MARKETING
    • 4.4.2. INDIRECT MARKETING
    • 4.4.3. MARKETING CHANNEL DEVELOPMENT TREND

5. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS

  • 5.1. OVERVIEW BY TARGETED ANTIGENS
  • 5.2. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS
  • 5.3. CD 19
    • 5.3.1. OVERVIEW
  • 5.4. CD 20
    • 5.4.1. OVERVIEW
  • 5.5. GD2
    • 5.5.1. OVERVIEW
  • 5.6. CD22
    • 5.6.1. OVERVIEW
  • 5.7. CD30
    • 5.7.1. OVERVIEW
  • 5.8. CD33
    • 5.8.1. OVERVIEW
  • 5.9. HER1
    • 5.9.1. OVERVIEW

6. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY APPLICATION

  • 6.1. OVERVIEW BY APPLICATION
  • 6.2. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY APPLICATION
  • 6.3. ACUTE LYMPHOCYTIC LEUKEMIA
    • 6.3.1. OVERVIEW
  • 6.4. CHRONIC LYMPHOCYTIC LEUKEMIA
    • 6.4.1. OVERVIEW
  • 6.5. NON HODGKIN LEUKEMIA
    • 6.5.1. OVERVIEW
  • 6.6. MULTIPLE MYELOMA
    • 6.6.1. OVERVIEW
  • 6.7. PANCREATIC CANCER
    • 6.7.1. OVERVIEW
  • 6.8. NEUROBLASTA
    • 6.8.1. OVERVIEW
  • 6.9. BREAST CANCER
    • 6.9.1. OVERVIEW

7. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. REGIONAL OUTLOOK
  • 7.2. INTRODUCTION
  • 7.3. NORTH AMERICA
    • 7.3.1. OVERVIEW
    • 7.3.2. NORTH AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY MARKET SEGMENT
    • 7.3.3. NORTH AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY
    • 7.3.4. UNITED STATE
    • 7.3.5. REST OF NORTH AMERICA
  • 7.4. EUROPE
    • 7.4.1. OVERVIEW
    • 7.4.2. EUROPE CAR T CELL THERAPY MARKET ESTIMATE BY MARKET SEGMENT
    • 7.4.3. EUROPE CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY
    • 7.4.4. UNITED KINGDOM
    • 7.4.5. FRANCE
    • 7.4.6. GERMANY
    • 7.4.7. REST OF EUROPE
  • 7.5. ASIA PACIFIC
    • 7.5.1. OVERVIEW
    • 7.5.2. ASIA PACIFIC CAR T CELL THERAPY MARKET ESTIMATE BY MARKET SEGMENT
    • 7.5.3. ASIA PACIFIC CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY
    • 7.5.4. CHINA
    • 7.5.5. JAPAN
    • 7.5.6. INDIA
    • 7.5.7. REST OF ASIA PACIFIC
  • 7.6. LATIN AMERICA
    • 7.6.1. OVERVIEW
    • 7.6.2. LATIN AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY MARKET SEGMENT
    • 7.6.3. LATIN AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY
    • 7.6.4. BRAZIL
    • 7.6.5. REST OF LATIN AMERICA
  • 7.7. MIDDLE EAST & AFRICA
    • 7.7.1. OVERVIEW
    • 7.7.2. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET ESTIMATE BY MARKET SEGMENT
    • 7.7.3. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY
    • 7.7.4. MIDDLE EAST
    • 7.7.5. AFRICA

8. COMPETITIVE LANDSCAPE OF THE CAR T CELL THERAPY COMPANIES

  • 8.1. CAR T CELL THERAPY MARKET COMPETITION
  • 8.2. PARTNERSHIP/COLLABORATION/AGREEMENT
  • 8.3. MERGER AND ACQUISITIONS
  • 8.4. NEW PRODUCT LAUNCH
  • 8.5. OTHER DEVELOPMENTS

9. COMPANY PROFILES OF CAR T CELL THERAPY INDUSTRY

  • 9.1. COMPANY SHARE ANALYSIS
  • 9.2. MARKET CONCENTRATION RATE
  • 9.3. BELLICUM PHARMACEUTICALS, INC.
    • 9.3.1. COMPANY OVERVIEW:
    • 9.3.2. FINANCIALS:
    • 9.3.3. PRODUCTS:
    • 9.3.4. RECENT DEVELOPMENTS:
  • 9.4. CELGENE CORPORATION
    • 9.4.1. COMPANY OVERVIEW:
    • 9.4.2. FINANCIALS:
    • 9.4.3. PRODUCTS:
    • 9.4.4. RECENT DEVELOPMENTS:
  • 9.5. CELLECTIS
    • 9.5.1. COMPANY OVERVIEW:
    • 9.5.2. FINANCIALS:
    • 9.5.3. PRODUCTS:
    • 9.5.4. RECENT DEVELOPMENTS:
  • 9.6. JUNO THERAPEUTICS
    • 9.6.1. COMPANY OVERVIEW:
    • 9.6.2. FINANCIALS:
    • 9.6.3. PRODUCTS:
    • 9.6.4. RECENT DEVELOPMENTS:
  • 9.7. KITE PHARMA INC.
    • 9.7.1. COMPANY OVERVIEW:
    • 9.7.2. FINANCIALS:
    • 9.7.3. PRODUCTS:
    • 9.7.4. RECENT DEVELOPMENTS:
  • 9.8. NOVARTIS INTERNATIONAL AG
    • 9.8.1. COMPANY OVERVIEW:
    • 9.8.2. FINANCIALS:
    • 9.8.3. PRODUCTS:
    • 9.8.4. RECENT DEVELOPMENTS:

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies  

LIST OF TABLES

  • TABLE 1. GLOBAL CAR T CELL THERAPY MARKET: SNAPSHOT
  • TABLE 2. DRIVERS OF THE GLOBAL CAR T CELL THERAPY MARKET: IMPACT ANALYSIS
  • TABLE 3. RESTRAINTS OF THE GLOBAL CAR T CELL THERAPY MARKET: IMPACT ANALYSIS
  • TABLE 4. LIST OF RAW MATERIAL
  • TABLE 5. LIST OF RAW MATERIAL MANUFACTURES
  • TABLE 6. LIST OF POTENTIAL BUYERS
  • TABLE 7. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 8. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD 19 BY GEOGRAPHY (USD MN)
  • TABLE 9. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD 20 BY GEOGRAPHY (USD MN)
  • TABLE 10. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN GD2 BY GEOGRAPHY (USD MN)
  • TABLE 11. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD22 BY GEOGRAPHY (USD MN)
  • TABLE 12. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD30 BY GEOGRAPHY (USD MN)
  • TABLE 13. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD33 BY GEOGRAPHY (USD MN)
  • TABLE 14. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN HER1 BY GEOGRAPHY (USD MN)
  • TABLE 15. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY APPLICATION (USD MN)
  • TABLE 16. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN ACUTE LYMPHOCYTIC LEUKEMIA BY GEOGRAPHY (USD MN)
  • TABLE 17. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA BY GEOGRAPHY (USD MN)
  • TABLE 18. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN NON HODGKIN LEUKEMIA BY GEOGRAPHY (USD MN)
  • TABLE 19. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN MULTIPLE MYELOMA BY GEOGRAPHY (USD MN)
  • TABLE 20. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN PANCREATIC CANCER BY GEOGRAPHY (USD MN)
  • TABLE 21. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN NEUROBLASTA BY GEOGRAPHY (USD MN)
  • TABLE 22. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN BREAST CANCER BY GEOGRAPHY (USD MN)
  • TABLE 23. GLOBAL CAR T CELL THERAPY MARKET BY GEOGRAPHY (USD MN)
  • TABLE 24. NORTH AMERICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 25. NORTH AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 26. NORTH AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 27. UNITED STATE CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 28. UNITED STATE CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 29. REST OF NORTH AMERICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 30. REST OF NORTH AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 31. EUROPE CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 32. EUROPE CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 33. EUROPE CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 34. UNITED KINGDOM CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 35. UNITED KINGDOM CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 36. FRANCE CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 37. FRANCE CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 38. GERMANY CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 39. GERMANY CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 40. REST OF EUROPE CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 41. REST OF EUROPE CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 42. ASIA PACIFIC CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 43. ASIA PACIFIC CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 44. ASIA PACIFIC CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 45. CHINA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 46. CHINA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 47. JAPAN CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 48. JAPAN CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 49. INDIA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 50. INDIA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 51. REST OF ASIA PACIFIC CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 52. REST OF ASIA PACIFIC CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 53. LATIN AMERICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 54. LATIN AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 55. LATIN AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 56. BRAZIL CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 57. BRAZIL CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 58. REST OF LATIN AMERICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 59. REST OF LATIN AMERICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 60. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 61. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 62. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET ESTIMATE BY COUNTRY (USD MN)
  • TABLE 63. MIDDLE EAST CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 64. MIDDLE EAST CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 65. AFRICA CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • TABLE 66. AFRICA CAR T CELL THERAPY MARKET ESTIMATE BY APPLICATION (USD MN)
  • TABLE 67. PARTNERSHIP/COLLABORATION/AGREEMENT
  • TABLE 68. MERGERS AND ACQUISITON
  • TABLE 69. NEW PRODUCT LAUNCH
  • TABLE 70. OTHER DEVELOPMENTS
  • TABLE 71. COMPANY MARKET SHARE ANALYSIS, 2018
  • TABLE 72. FINANCIAL HIGHLIGHTS
  • TABLE 73. MAJOR PRODUCTS
  • TABLE 74. FINANCIAL HIGHLIGHTS
  • TABLE 75. MAJOR PRODUCTS
  • TABLE 76. FINANCIAL HIGHLIGHTS
  • TABLE 77. MAJOR PRODUCTS
  • TABLE 78. FINANCIAL HIGHLIGHTS
  • TABLE 79. MAJOR PRODUCTS
  • TABLE 80. FINANCIAL HIGHLIGHTS
  • TABLE 81. MAJOR PRODUCTS
  • TABLE 82. FINANCIAL HIGHLIGHTS
  • TABLE 83. MAJOR PRODUCTS

LIST OF FIGURES

  • FIG. 1. RESEARCH SCOPE OF CAR T CELL THERAPY REPORT
  • FIG. 1. MARKET RESEARCH PROCESS
  • FIG. 2. MARKET RESEARCH METHODOLOGY
  • FIG. 3. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY REGION (USD MN)
  • FIG. 4. PORTERS FIVE FORCES ANALYSIS
  • FIG. 5. MARKET ATTRACTIVENESS ANALYSIS BY TARGETED ANTIGENS
  • FIG. 6. MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
  • FIG. 7. MARKET ATTRACTIVENESS ANALYSIS BY REGION
  • FIG. 8. VALUE CHAIN ANALYSIS
  • FIG. 9. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY TARGETED ANTIGENS (USD MN)
  • FIG. 10. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD 19 BY REGION
  • FIG. 11. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD 20 BY REGION
  • FIG. 12. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN GD2 BY REGION
  • FIG. 13. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD22 BY REGION
  • FIG. 14. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CD30 BY REGION
  • FIG. 15. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY APPLICATION (USD MN)
  • FIG. 16. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN ACUTE LYMPHOCYTIC LEUKEMIA BY REGION
  • FIG. 17. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA BY REGION
  • FIG. 18. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN NON HODGKIN LEUKEMIA BY REGION
  • FIG. 19. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN MULTIPLE MYELOMA BY REGION
  • FIG. 20. GLOBAL CAR T CELL THERAPY MARKET ANALYSIS IN PANCREATIC CANCER BY REGION
  • FIG. 21. GLOBAL CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 22. NORTH AMERICA CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 23. EUROPE CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 24. ASIA PACIFIC CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 25. LATIN AMERICA CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 26. MIDDLE EAST & AFRICA CAR T CELL THERAPY MARKET BY REVENUE
  • FIG. 27. RECENT DEVELOPMENT IN CAR T CELL THERAPY INDUSTRY
  • FIG. 28. COMPANY MARKET SHARE ANALYSIS, 2018
Back to Top